Ovid to present posters on pipeline program for neuronal hyperexcitability

Ovid Therapeutics (OVID) will present four posters that support the Company’s OV329 and OV350 pipeline programs for the treatment of conditions caused by neuronal hyperexcitability at the 2024 American Epilepsy Society Annual Meeting in Los Angeles, California. “We are encouraged by the results of preclinical studies comparing OV329 to vigabatrin, which further elucidate OV329’s pharmacodynamic and safety profile, including its lack of accumulation in the brain, retina, and eye,” said Zhong Zhong, Ph.D., Chief Scientific Officer of Ovid Therapeutics. “These findings, alongside preclinical studies demonstrating rapid exposure in the brain, further support OV329’s potential to be a best-in-class GABA-aminotransferase inhibitor. GABA-AT inhibition is a proven mechanism of action, yet it has had limited clinical use over the years due to reported ocular toxicities associated with the first-generation medicine. OV329 may address the therapeutic needs of patients seeking anti-convulsant efficacy and improved safety without sedation. Additionally, we are excited by new findings that reinforce OV350’s activity in terminating seizures and providing neuroprotective benefits in animals. OV350 is the first of multiple programs we are developing that directly activate the potassium chloride co-transporter 2, a fundamental target in restoring inhibitory/excitatory balance. Next year, we hope to be the first company to study a KCC2 direct activator in humans.”